Carla Scaroni

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2105823/publications.pdf

Version: 2024-02-01

210 papers	7,712 citations	50276 46 h-index	74163 75 g-index
227 all docs	227 docs citations	227 times ranked	5127 citing authors

#	Article	IF	Citations
1	Traumatic brain injury and subarachnoid haemorrhage are conditions at high risk for hypopituitarism: screening study at 3Âmonths after the brain injury. Clinical Endocrinology, 2004, 61, 320-326.	2.4	330
2	Residual Pituitary Function after Brain Injury-Induced Hypopituitarism: A Prospective 12-Month Study. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 6085-6092.	3.6	319
3	Consensus on diagnosis and management of Cushing's disease: a guideline update. Lancet Diabetes and Endocrinology,the, 2021, 9, 847-875.	11.4	315
4	Risk Factors and Long-Term Follow-Up of Adrenal Incidentalomas1. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 520-526.	3.6	203
5	Predictors of morbidity and mortality in acromegaly: an Italian survey. European Journal of Endocrinology, 2012, 167, 189-198.	3.7	189
6	Risk Factors and Long-Term Follow-Up of Adrenal Incidentalomas. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 520-526.	3.6	173
7	The diagnostic performance of urinary free cortisol is better than the cortisol:cortisone ratio in detecting de novo Cushing's syndrome: the use of a LCâ€“MS/MS method in routine clinical practice. European Journal of Endocrinology, 2014, 171, 1-7.	3.7	161
8	Incidentally Discovered Adrenal Tumors: Endocrine and Scintigraphic Correlates1. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 55-62.	3.6	160
9	Incidentally Discovered Adrenal Tumors: Endocrine and Scintigraphic Correlates. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 55-62.	3.6	127
10	A Novel Mutation in the Upstream Open Reading Frame of the CDKN1B Gene Causes a MEN4 Phenotype. PLoS Genetics, 2013, 9, e1003350.	3.5	125
11	The hypertension of Cushing's syndrome. Journal of Hypertension, 2015, 33, 44-60.	0.5	125
12	Conventional and Nuclear Medicine Imaging in Ectopic Cushing's Syndrome: A Systematic Review. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 3231-3244.	3.6	113
13	Cryptic 21-Hydroxylase Deficiency in Families of Patients with Classical Congenital Adrenal Hyperplasia*. Journal of Clinical Endocrinology and Metabolism, 1980, 51, 1316-1324.	3.6	110
14	Cardiovascular Risk Factors and Ultrasound Evaluation of Intima-Media Thickness at Common Carotids, Carotid Bulbs, and Femoral and Abdominal Aorta Arteries in Patients with Classic Congenital Adrenal Hyperplasia due to 21-Hydroxylase Deficiency. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 1015-1018.	3.6	109
15	Potential Role for Retinoic Acid in Patients with Cushing's Disease. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 3577-3583.	3.6	105
16	Temozolomide therapy in patients with aggressive pituitary adenomas or carcinomas. Journal of Neuro-Oncology, 2016, 126, 519-525.	2.9	105
17	COVID-19 infection and glucocorticoids: update from the Italian Society of Endocrinology Expert Opinion on steroid replacement in adrenal insufficiency. Journal of Endocrinological Investigation, 2020, 43, 1141-1147.	3.3	103
18	Spironolactone in the treatment of polycystic ovary syndrome: Effects on clinical features, insulin sensitivity and lipid profile. Journal of Endocrinological Investigation, 2005, 28, 49-53.	3.3	88

#	Article	IF	Citations
19	Glucose Metabolism Abnormalities in Cushing Syndrome: From Molecular Basis to Clinical Management. Endocrine Reviews, 2017, 38, 189-219.	20.1	88
20	Combination therapy for Cushingâ€™s disease: effectiveness of two schedules of treatment. Should we start with cabergoline or ketoconazole?. Pituitary, 2014, 17, 109-117.	2.9	86
21	Licorice reduces serum testosterone in healthy women. Steroids, 2004, 69, 763-766.	1.8	84
22	Delta Infection and Liver Disease in Hemophilic Carriers of Hepatitis B Surface Antigen. Journal of Infectious Diseases, 1982, 145, 18-22.	4.0	83
23	The Role of Unilateral Adrenalectomy in ACTHâ€Independent Macronodular Adrenal Hyperplasia (AIMAH). World Journal of Surgery, 2008, 32, 882-889.	1.6	82
24	Effect of protracted treatment with rosiglitazone, a PPARÎ³ agonist, in patients with Cushing's disease. Clinical Endocrinology, 2006, 64, 219-224.	2.4	80
25	Genetic and Hormonal Characterization of Cryptic 21-Hydroxylase Deficiency*. Journal of Clinical Endocrinology and Metabolism, 1981, 53, 1193-1197.	3.6	77
26	Performance of salivary cortisol in the diagnosis of Cushing's syndrome, adrenal incidentaloma, and adrenal insufficiency. European Journal of Endocrinology, 2013, 169, 31-36.	3.7	69
27	Time to Diagnosis in Cushingâ€™s Syndrome: A Meta-Analysis Based on 5367 Patients. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e12-e22.	3.6	69
28	The role of inferior petrosal sinus sampling in ACTH-dependent Cushing's syndrome: review and joint opinion statement by members of the Italian Society for Endocrinology, Italian Society for Neurosurgery, and Italian Society for Neuroradiology. Neurosurgical Focus, 2015, 38, E5.	2.3	68
29	Prognostic factors in ectopic Cushingâ€™s syndrome due to neuroendocrine tumors: a multicenter study. European Journal of Endocrinology, 2017, 176, 453-461.	3.7	66
30	Genetic Landscape of Sporadic Unilateral Adrenocortical Adenomas Without PRKACA p.Leu206Arg Mutation. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 3526-3538.	3.6	65
31	An analysis of different therapeutic options in patients with <scp>C</scp>ushing's syndrome due to bilateral macronodular adrenal hyperplasia: a singleâ€centre experience. Clinical Endocrinology, 2015, 82, 808-815.	2.4	62
32	A multicenter experience on the prevalence of ARMC5 mutations in patients with primary bilateral macronodular adrenal hyperplasia: from genetic characterization to clinical phenotype. Endocrine, 2017, 55, 959-968.	2.3	62
33	Hypopituitarism induced by traumatic brain injury in the transition phase. Journal of Endocrinological Investigation, 2005, 28, 984-989.	3.3	61
34	Treatment of polycystic ovary syndrome with spironolactone plus licorice. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2007, 131, 61-67.	1.1	61
35	Acromegaly is associated with increased cancer risk: a survey in Italy. Endocrine-Related Cancer, 2017, 24, 495-504.	3.1	61
36	Diagnosis and complications of Cushing's disease: genderâ€related differences. Clinical Endocrinology, 2014, 80, 403-410.	2.4	60

#	Article	IF	Citations
37	Cushing's syndrome: Overview of clinical presentation, diagnostic tools and complications. Best Practice and Research in Clinical Endocrinology and Metabolism, 2020, 34, 101380.	4.7	60
38	Patients with Cushingâ€™s Syndrome Have Increased Intimal Media Thickness at Different Vascular Levels: Comparison with a Population Matched for Similar Cardiovascular Risk Factors. Hormone and Metabolic Research, 2006, 38, 405-410.	1.5	58
39	Increased Rate of Intracranial Saccular Aneurysms in Acromegaly: An MR Angiography Study and Review of the Literature. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 1292-1300.	3.6	56
40	Screening Tests for Cushing's Syndrome: Urinary Free Cortisol Role Measured by LC-MS/MS. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 3856-3861.	3.6	56
41	Prevalence of AIP mutations in a large series of sporadic Italian acromegalic patients and evaluation of CDKN1B status in acromegalic patients with multiple endocrine neoplasia. European Journal of Endocrinology, 2010, 163, 369-376.	3.7	53
42	Coagulopathy in Cushingâ€™s Syndrome. Neuroendocrinology, 2010, 92, 55-59.	2.5	52
43	Second-line tests in the differential diagnosis of ACTH-dependent Cushingâ€™s syndrome. Pituitary, 2016, 19, 488-495.	2.9	52
44	Somatostatin analogues increase AIP expression in somatotropinomas, irrespective of Gsp mutations. Endocrine-Related Cancer, 2013, 20, 753-766.	3.1	50
45	Temozolomide and pasireotide treatment for aggressive pituitary adenoma: expertise at a tertiary care center. Journal of Neuro-Oncology, 2015, 122, 189-196.	2.9	50
46	The Pathophysiology and Treatment of Hypertension in Patients With Cushing's Syndrome. Frontiers in Endocrinology, 2019, 10, 321.	3.5	50
47	Treatment of skeletal impairment in patients with endogenous hypercortisolism: when and how?. Osteoporosis International, 2014, 25, 441-446.	3.1	49
48	Hypopituitarism and growth hormone deficiency (GHD) after traumatic brain injury (TBI). Growth Hormone and IGF Research, 2004, 14, 114-117.	1.1	46
49	The usefulness of combined biochemical tests in the diagnosis of Cushingâ€™s disease with negative pituitary magnetic resonance imaging. European Journal of Endocrinology, 2007, 156, 241-248.	3.7	46
50	Perioperative thromboprophylaxis in Cushingâ€™s disease: What we did and what we are doing?. Pituitary, 2015, 18, 487-493.	2.9	45
51	Effect of Angiotensin II and Converting Enzyme Inhibitor (Captopril) on Blood Pressure, Plasma Renin Activity and Aldosterone in Primary Aldosteronism. Clinical Science, 1981, 61, 289s-293s.	0.0	44
52	Somatostatin analogs and gallstones: A retrospective survey on a large series of acromegalic patients. Journal of Endocrinological Investigation, 2008, 31, 704-710.	3.3	44
53	Metyrapone treatment in Cushingâ€™s syndrome: a real-life study. Endocrine, 2018, 62, 701-711.	2.3	44
54	The R304X mutation of the aryl hydrocarbon receptor interacting protein gene in familial isolated pituitary adenomas: Mutational hot-spot or founder effect?. Journal of Endocrinological Investigation, 2010, 33, 800-805.	3.3	43

#	Article	IF	Citations
55	Predicting late recurrence in surgically treated patients with <scp>C</scp>ushing's disease. Clinical Endocrinology, 2013, 79, 394-401.	2.4	42
56	Diabetes Mellitus Secondary to Cushingâ€™s Disease. Frontiers in Endocrinology, 2018, 9, 284.	3.5	42
57	Long-term treatment of Cushingâ€™s disease with pasireotide: 5-year results from an open-label extension study of a Phase III trial. Endocrine, 2017, 57, 156-165.	2.3	40
58	Rapid disease progression in patient with mismatch-repair deficiency pituitary ACTH-secreting adenoma treated with checkpoint inhibitor pembrolizumab. Anti-Cancer Drugs, 2020, 31, 199-204.	1.4	40
59	The Glucose-Dependent Insulinotropic Polypeptide Receptor is Overexpressed Amongst GNAS1 Mutation-Negative Somatotropinomas and Drives Growth Hormone (GH)-Promoter Activity in GH3 Cells. Journal of Neuroendocrinology, 2011, 23, 641-649.	2.6	39
60	The GIP/GIPR axis is functionally linked to GH-secretion increase in a significant proportion of gspâ^' somatotropinomas. European Journal of Endocrinology, 2017, 176, 543-553.	3.7	39
61	Including Relative Adrenal Insufficiency in Definition and Classification of Acute-on-Chronic Liver Failure. Clinical Gastroenterology and Hepatology, 2020, 18, 1188-1196.e3.	4.4	39
62	Approach to patients with pseudo-Cushingâ€™s states. Endocrine Connections, 2020, 9, R1-R13.	1.9	39
63	Deletion within theCYP17 Gene Together with Insertion of Foreign DNA Is the Cause of Combined Complete 17Î±-Hydroxylase/17,20-Lyase Deficiency in an Italian Patient. Molecular Endocrinology, 1991, 5, 2037-2045.	3.7	38
64	Food-dependent Cushing's syndrome: from molecular characterization to therapeutical results. European Journal of Endocrinology, 2007, 157, 771-778.	3.7	38
65	Volumetric MRI analysis of hippocampal subregions in Cushing's disease: A model for glucocorticoid neural modulation. European Psychiatry, 2011, 26, 64-67.	0.2	38
66	Long-term glucocorticoid effect on bone mineral density in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. European Journal of Endocrinology, 2016, 175, 101-106.	3.7	36
67	Glucocorticoid excess and COVID-19 disease. Reviews in Endocrine and Metabolic Disorders, 2021, 22, 703-714.	5.7	36
68	Dexamethasone measurement during low-dose suppression test for suspected hypercortisolism: threshold development with and validation. Journal of Endocrinological Investigation, 2020, 43, 1105-1113.	3.3	36
69	A venous thromboembolism risk assessment model for patients with Cushingâ€™s syndrome. Endocrine, 2016, 52, 322-332.	2.3	35
70	Venous thromboembolism in patients with Cushingâ€™s syndrome: need of a careful investigation of the prothrombotic risk profile. Pituitary, 2013, 16, 175-181.	2.9	34
71	Acromegaly Is More Severe in Patients With AHR or AIP Gene Variants Living in Highly Polluted Areas. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 1872-1879.	3.6	34
72	Loss of KDM1A in GIP-dependent primary bilateral macronodular adrenal hyperplasia with Cushing's syndrome: a multicentre, retrospective, cohort study. Lancet Diabetes and Endocrinology,the, 2021, 9, 813-824.	11.4	34

#	Article	IF	Citations
73	Cyclic Cushing's Syndrome: An Overview. Pituitary, 2004, 7, 203-207.	2.9	33
74	The medical treatment with pasireotide in Cushingâ€™s disease: an Italian multicentre experience based on â€œreal-world evidenceâ€. Endocrine, 2019, 64, 657-672.	2.3	33
75	Activation of the Dopamine Receptor Type-2 (DRD2) Promoter by 9-Cis Retinoic Acid in a Cellular Model of Cushing's Disease Mediates the Inhibition of Cell Proliferation and ACTH Secretion Without a Complete Corticotroph-to-Melanotroph Transdifferentiation. Endocrinology, 2014, 155, 3538-3549.	2.8	32
76	Early recognition of aggressive pituitary adenomas: a single-centre experience. Acta Neurochirurgica, 2018, 160, 49-55.	1.7	32
77	The Effects of Iodine Supplementation in Pregnancy on Iodine Status, Thyroglobulin Levels and Thyroid Function Parameters: Results from a Randomized Controlled Clinical Trial in a Mild-to-Moderate Iodine Deficiency Area. Nutrients, 2019, 11, 2639.	4.1	32
78	Daily salivary cortisol and cortisone rhythm in patients with adrenal incidentaloma. Endocrine, 2018, 59, 510-519.	2.3	32
79	Mitotane Concentrations Influence the Risk of Recurrence in Adrenocortical Carcinoma Patients on Adjuvant Treatment. Journal of Clinical Medicine, 2019, 8, 1850.	2.4	31
80	Assessment of glucocorticoid therapy with salivary cortisol in secondary adrenal insufficiency. European Journal of Endocrinology, 2012, 167, 769-776.	3.7	30
81	Analysis of GPR101 and AIP genes mutations in acromegaly: a multicentric study. Endocrine, 2016, 54, 762-767.	2.3	30
82	Italian Society for the Study of Diabetes (SID)/Italian Endocrinological Society (SIE) guidelines on the treatment of hyperglycemia in Cushingâ€™s syndrome and acromegaly. Journal of Endocrinological Investigation, 2016, 39, 235-255.	3.3	30
83	First-line screening tests for Cushingâ€™s syndrome in patients with adrenal incidentaloma: the role of urinary free cortisol measured by LC-MS/MS. Journal of Endocrinological Investigation, 2017, 40, 753-760.	3.3	30
84	What we have to know about corticosteroids use during Sars-Cov-2 infection. Journal of Endocrinological Investigation, 2021, 44, 693-701.	3.3	30
85	Polymorphisms in von Willebrand factor gene promoter influence the glucocorticoidâ€induced increase in von Willebrand factor: the lesson learned from Cushing syndrome. British Journal of Haematology, 2008, 140, 230-235.	2.5	29
86	Approach to hyponatremia according to the clinical setting: Consensus statement from the Italian Society of Endocrinology (SIE), Italian Society of Nephrology (SIN), and Italian Association of Medical Oncology (AIOM). Journal of Endocrinological Investigation, 2018, 41, 3-19.	3.3	28
87	Autoimmune polyendocrine syndrome type 1: an Italian survey on 158 patients. Journal of Endocrinological Investigation, 2021, 44, 2493-2510.	3.3	28
88	AHR Over-Expression in Papillary Thyroid Carcinoma: Clinical and Molecular Assessments in a Series of Italian Acromegalic Patients with a Long-Term Follow-Up. PLoS ONE, 2014, 9, e101560.	2.5	27
89	A meta-iodobenzylguanidine scintigraphic scoring system increases accuracy in the diagnostic management of pheochromocytoma. Endocrine-Related Cancer, 2006, 13, 525-533.	3.1	25
90	Long-course temozolomide in aggressive pituitary adenoma: real-life experience in two tertiary care centers and review of the literature. Pituitary, 2020, 23, 359-366.	2.9	25

#	Article	IF	Citations
91	Sleep apnea syndrome in endocrine clinics. Journal of Endocrinological Investigation, 2015, 38, 827-834.	3.3	24
92	Improved salivary cortisol rhythm with dual-release hydrocortisone. Endocrine Connections, 2018, 7, 965-974.	1.9	24
93	Central adrenal insufficiency: open issues regarding diagnosis and glucocorticoid treatment. Clinical Chemistry and Laboratory Medicine, 2019, 57, 1125-1135.	2.3	24
94	Paradoxical GH Increase During OGTT Is Associated With First-Generation Somatostatin Analog Responsiveness in Acromegaly. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 856-862.	3.6	23
95	A constitutive active MAPK/ERK pathway due to BRAFV600E positively regulates AHR pathway in PTC. Oncotarget, 2015, 6, 32104-32114.	1.8	23
96	17-Î±-hydroxylase deficiency in three siblings: short- and long-term studies. Journal of Endocrinological Investigation, 1991, 14, 99-108.	3.3	22
97	Cortisol and cortisone ratio in urine: LC-MS/MS method validation and preliminary clinical application. Clinical Chemistry and Laboratory Medicine, 2014, 52, 213-20.	2.3	22
98	Thrombin generation in Cushingâ€™s Syndrome: do the conventional clotting indices tell the whole truth?. Pituitary, 2014, 17, 68-75.	2.9	22
99	Clinical use of pasireotide for Cushing's disease in adults. Therapeutics and Clinical Risk Management, 2015, 11, 425.	2.0	22
100	Human Corticotropin-Releasing Hormone Tests: 10 Years of Real-Life Experience in Pituitary and Adrenal Disease. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e3938-e3949.	3.6	22
101	COVID-19 outbreak and steroids administration: are patients treated for Sars-Cov-2 at risk of adrenal insufficiency?. Journal of Endocrinological Investigation, 2020, 43, 1035-1036.	3.3	22
102	Diagnostic Accuracy of CT Texture Analysis in Adrenal Masses: A Systematic Review. International Journal of Molecular Sciences, 2022, 23, 637.	4.1	22
103	Inhibitory effect of somatostatin on the aldosterone response to angiotensin II: in vitro studies. Journal of Endocrinological Investigation, 1982, 5, 173-177.	3.3	21
104	Hypopituitarism findings in patients with primary brain tumors 1 year after neurosurgical treatment: Preliminary report. Journal of Endocrinological Investigation, 2006, 29, 516-522.	3.3	21
105	Practical Considerations for the Management of Cushing's Disease and COVID-19: A Case Report. Frontiers in Endocrinology, 2020, 11, 554.	3.5	21
106	Cyclic Cushing's syndrome: an overview. Arquivos Brasileiros De Endocrinologia E Metabologia, 2007, 51, 1253-1260.	1.3	21
107	Intracranial internal carotid artery changes in acromegaly: a quantitative magnetic resonance angiography study. Pituitary, 2014, 17, 414-422.	2.9	20
108	Diagnostic accuracy of increased urinary cortisol/cortisone ratio to differentiate ACTHâ€dependent Cushing's syndrome. Clinical Endocrinology, 2017, 87, 500-507.	2.4	19

#	Article	IF	Citations
109	Crude extract of Origanum vulgare L. induced cell death and suppressed MAPK and PI3/Akt signaling pathways in SW13 and H295R cell lines. Natural Product Research, 2019, 33, 1646-1649.	1.8	19
110	Targeted Metabolomics as a Tool in Discriminating Endocrine From Primary Hypertension. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e1111-e1128.	3.6	19
111	Adrenal morpho-functional alterations in patients with acromegaly. Journal of Endocrinological Investigation, 2008, 31, 602-606.	3.3	18
112	Persistent increase of osteoprotegerin levels after cortisol normalization in patients with Cushing's syndrome. European Journal of Endocrinology, 2010, 162, 85-90.	3.7	18
113	Steroids and hypertension. Journal of Steroid Biochemistry and Molecular Biology, 1991, 40, 35-44.	2.5	17
114	The pathogenic role of the GIP/GIPR axis in human endocrine tumors: emerging clinical mechanisms beyond diabetes. Reviews in Endocrine and Metabolic Disorders, 2020, 21, 165-183.	5.7	17
115	HLA genotypes and HLA-linked genetic markers in Italian patients with classical 21-hydroxylase deficiency. Human Genetics, 1981, 58, 331-337.	3.8	16
116	Low-dose ketoconazole treatment in hirsute women. Journal of Endocrinological Investigation, 1990, 13, 35-40.	3.3	16
117	Clinical and Genetic Aspects of Phaeochromocytoma. Hormone Research in Paediatrics, 2003, 59, 56-61.	1.8	16
118	Idiopathic primary hyperaldosteronism: Normalization of plasma aldosterone after one month withdrawal of long-term therapy with aldosterone-receptor antagonist potassium canrenoate. Journal of Endocrinological Investigation, 2005, 28, 236-240.	3.3	16
119	Assessment of the awareness and management of sleep apnea syndrome in acromegaly. The COM.E.TA (Comorbidities Evaluation and Treatment in Acromegaly) Italian Study Group. Journal of Endocrinological Investigation, 2011, 34, 60-64.	3.3	16
120	New Insight into the Hypercoagulability of Cushingâ€™s Syndrome. Neuroendocrinology, 2011, 93, 121-125.	2.5	16
121	Pasireotide treatment reduces cardiometabolic risk in Cushingâ€™s disease patients: an Italian, multicenter study. Endocrine, 2018, 61, 118-124.	2.3	16
122	Secondary Arterial Hypertension: From Routine Clinical Practice to Evidence in Patients with Adrenal Tumor. High Blood Pressure and Cardiovascular Prevention, 2018, 25, 345-354.	2.2	16
123	Aldosterone in Gynecology and Its Involvement on the Risk of Hypertension in Pregnancy. Frontiers in Endocrinology, 2019, 10, 575.	3.5	16
124	Activation profiles of monocyte-macrophages and HDL function in healthy women in relation to menstrual cycle and in polycystic ovary syndrome patients. Endocrine, 2019, 66, 360-369.	2.3	16
125	Peroxisome Proliferator-Activated Receptor ? in the Human Pituitary Gland: Expression and Splicing Pattern in Adenomas Versus Normal Pituitary. Journal of Neuroendocrinology, 2007, 19, 552-559.	2.6	15
126	Pharmacological Approaches to Controlling Cardiometabolic Risk in Women with PCOS. International Journal of Molecular Sciences, 2020, 21, 9554.	4.1	15

#	Article	IF	Citations
127	A multidisciplinary approach to the management of adrenal incidentaloma. Expert Review of Endocrinology and Metabolism, 2021, 16, 201-212.	2.4	15
128	Second-Line Tests in the Diagnosis of Adrenocorticotropic Hormone-Dependent Hypercortisolism. Annals of Laboratory Medicine, 2021, 41, 521-531.	2.5	15
129	Indication to dynamic and invasive testing in Cushingâ€™s disease according to different neuroradiological findings. Journal of Endocrinological Investigation, 2022, 45, 629-637.	3.3	15
130	Pharmacokinetics of oral and rectal flurbiprofen in children. European Journal of Clinical Pharmacology, 1984, 27, 367-369.	1.9	14
131	Investigation of N-cadherin/Î²-catenin expression in adrenocortical tumors. Tumor Biology, 2016, 37, 13545-13555.	1.8	14
132	Effects of pasireotide treatment on coagulative profile: a prospective study in patients with Cushingâ€™s disease. Endocrine, 2018, 62, 207-214.	2.3	14
133	Biological effects and potential mechanisms of action of Pistacia lentiscus Chios mastic extract in Caco-2 cell model. Journal of Functional Foods, 2019, 54, 92-97.	3.4	14
134	Frequently asked questions and answers (if any) in patients with adrenal incidentaloma. Journal of Endocrinological Investigation, 2021, 44, 2749-2763.	3.3	14
135	Pasireotide-Induced Shrinkage in GH and ACTH Secreting Pituitary Adenoma: A Systematic Review and Meta-Analysis. Frontiers in Endocrinology, 0, 13, .	3.5	14
136	Gonadotropin secreting pituitary adenoma associated with erythrocytosis: case report and literature review. Hormones, 2014, 13, 131-139.	1.9	13
137	Age and the metabolic syndrome affect salivary cortisol rhythm: data from a community sample. Hormones, 2015, 14, 392-8.	1.9	13
138	The aurora kinase inhibitor VX-680 shows anti-cancer effects in primary metastatic cells and the SW13 cell line. Investigational New Drugs, 2016, 34, 531-540.	2.6	13
139	Preoperative treatment with metyrapone in patients with Cushingâ€™s syndrome due to adrenal adenoma: a pilot prospective study. Endocrine Connections, 2018, 7, 1227-1235.	1.9	13
140	A New Clinical Model to Estimate the Pre-Test Probability of Cushingâ€™s Syndrome: The Cushing Score. Frontiers in Endocrinology, 2021, 12, 747549.	3.5	13
141	No Linkage between HLA and Congenital Adrenal Hyperplasia Due to 17-Alpha-Hydroxylase Deficiency. New England Journal of Medicine, 1980, 303, 530-530.	27.0	12
142	New Aspects of Mineralocorticoid Hypertension. Hormone Research, 1990, 34, 175-180.	1.8	12
143	Growth hormone and insulin-like growth factor I in a Sydney Olympic gold medallist. British Journal of Sports Medicine, 2002, 36, 148-149.	6.7	12
144	Unilateral Adrenal Tumor, Erectile Dysfunction and Infertility in a Patient with 21-Hydroxylase Deficiency: Effects of Glucocorticoid Treatment and Surgery. Experimental and Clinical Endocrinology and Diabetes, 2003, 111, 41-43.	1.2	12

#	Article	IF	Citations
145	The role of an acute pasireotide suppression test in predicting response to treatment in patients with Cushingâ€™s disease: findings from a pilot study. Endocrine, 2015, 50, 154-161.	2.3	12
146	Perioperative multidisciplinary management of endoscopic transsphenoidal surgery for sellar lesions: practical suggestions from the Padova model. Neurosurgical Review, 2020, 43, 1109-1116.	2.4	12
147	Pituitary-adrenal axis and peripheral cortisol metabolism in obese patients. Endocrine, 2020, 69, 386-392.	2.3	12
148	Attenuation Value in Adrenal Incidentalomas: A Longitudinal Study. Frontiers in Endocrinology, 2021, 12, 794197.	3.5	12
149	The Multiple Effects of Vitamin D against Chronic Diseases: From Reduction of Lipid Peroxidation to Updated Evidence from Clinical Studies. Antioxidants, 2022, 11, 1090.	5.1	12
150	Effect of Short-term Therapy with Recombinant Human Growth Hormone (GH) on Metabolic Parameters and Preclinical Atherosclerotic Markers in Hypopituitary Patients with Growth Hormone Deficiency. Hormone and Metabolic Research, 2006, 38, 16-21.	1.5	11
151	Microsatellite (GT)n is part of the von Willebrand factor (VWF) promoter region that influences the glucocorticoid-induced increase in VWF in Cushing's syndrome. Thrombosis Research, 2010, 125, e275-e280.	1.7	11
152	Clinical presentation and management of acromegaly in elderly patients. Hormones, 2021, 20, 143-150.	1.9	11
153	Microsatellite (GT)n repeats and SNPs in the von Willebrand factor gene promoter do not influence circulating von Willebrand factor levels under normal conditions. Thrombosis and Haemostasis, 2009, 101, 298-304.	3.4	11
154	High Prevalence of Thyroid Ultrasonographic Abnormalities in Primary Aldosteronism. Endocrine, 2003, 22, 155-160.	2.2	10
155	Assessment of the awareness and management of cardiovascular complications of acromegaly in Italy. The COM.E.T.A. (COMorbidities Evaluation and Treatment in Acromegaly) Study. Journal of Endocrinological Investigation, 2008, 31, 731-738.	3.3	10
156	Herniation of cerebellar tonsils in acromegaly: prevalence, pathogenesis and clinical impact. Pituitary, 2013, 16, 122-130.	2.9	10
157	Anastrozole as add-on therapy for cabergoline-resistant prolactin-secreting pituitary adenomas: real-life experience in male patients. Pituitary, 2021, 24, 914-921.	2.9	10
158	Adrenal nodules in patients with Cushing's disease: prevalence, clinical significance and follow-up. Journal of Endocrinological Investigation, 2011, 34, e204-9.	3.3	10
159	Efficacy and safety of high-dose long-acting repeatable octreotide as monotherapy or in combination with pegvisomant or cabergoline in patients with acromegaly not adequately controlled by conventional regimens: results of an open-label, multicentre study. Endokrynologia Polska, 2019, 70, 305-312.	1.0	10
160	Renin-Angiotensin-Aldosterone System: A Long-Term Follow-Up Study in 17Î±-Hydroxylase Deficiency Syndrome (17OHDS). Clinical and Experimental Hypertension, 1986, 8, 773-780.	0.3	9
161	Adrenal lesions in acromegaly: Do metabolic aspects and aryl hydrocarbon receptor interacting protein gene have a role? Evaluation at baseline and after long-term follow-up. Journal of Endocrinological Investigation, 2011, 34, 353-360.	3.3	9
162	Therapeutic strategies for Cushingâ€™s syndrome: an update. Expert Opinion on Orphan Drugs, 2015, 3, 45-56.	0.8	9

#	Article	IF	Citations
163	Italian Society for the Study of Diabetes (SID)/Italian Endocrinological Society (SIE) guidelines on the treatment of hyperglycemia in Cushing's syndrome and acromegaly. Nutrition, Metabolism and Cardiovascular Diseases, 2016, 26, 85-102.	2.6	9
164	Decrease in salivary cortisol levels after glucocorticoid dose reduction in patients with adrenal insufficiency: A prospective proofâ€ofâ€concept study. Clinical Endocrinology, 2018, 88, 201-208.	2.4	9
165	Analysis of characteristics and outcomes by growth hormone treatment duration in adult patients in the Italian cohort of the Hypopituitary Control and Complications Study (HypoCCS). Journal of Endocrinological Investigation, 2018, 41, 1259-1266.	3.3	9
166	Letter to Editor: Reply to R.T. Casey (Semin Oncol. 2018 Jun;45(3):151-155). Seminars in Oncology, 2019, 46, 104-105.	2.2	9
167	The GIP/GIPR axis in medullary thyroid cancer: clinical and molecular findings. Endocrine-Related Cancer, 2022, 29, 273-284.	3.1	9
168	Circadian Secretion of Acth, Cortisol, and Mineralocorticoids in Cushing's Syndrome. Clinical and Experimental Hypertension, 1982, 4, 1779-1794.	0.3	8
169	Peripheral and Renal Vein Plasma Renin Activity in Hypertensive Urological Patients. British Journal of Urology, 1982, 54, 348-353.	0.1	8
170	Furosemide and 11Î²-hydroxysteroid dehydrogenase activity, in man. Experimental and Clinical Endocrinology and Diabetes, 2002, 110, 272-276.	1.2	8
171	The role of 68Ga-DOTA derivatives PET-CT in patients with ectopic ACTH syndrome. Endocrine Connections, 2020, 9, 337-345.	1.9	8
172	Current clinical practice for thromboprophylaxis management in patients with Cushingâ€™s syndrome across reference centers of the European Reference Network on Rare Endocrine Conditions (Endo-ERN). Orphanet Journal of Rare Diseases, 2022, 17, 178.	2.7	8
173	The M235T polymorphism of the angiotensinogen gene in women with polycystic ovary syndrome. Fertility and Sterility, 2005, 84, 1520-1521.	1.0	7
174	Radiotherapy in acromegaly: Long-term brain parenchymal and vascular magnetic resonance changes. Journal of Neuroradiology, 2018, 45, 323-328.	1.1	7
175	Temozolomide cytoreductive treatment in a giant cabergoline-resistant prolactin-secreting pituitary neuroendocrine tumor. Anti-Cancer Drugs, 2019, 30, 533-536.	1.4	7
176	New insights to the potential mechanisms driving coronary flow reserve impairment in Cushing's syndrome: A pilot noninvasive study by transthoracic Doppler echocardiography. Microvascular Research, 2020, 128, 103940.	2.5	7
177	Is pasireotide-induced diabetes mellitus predictable? A pilot study on the effect of a single dose of pasireotide on glucose homeostasis. Pituitary, 2020, 23, 534-542.	2.9	7
178	Identification of glucocorticoid-related molecular signature by whole blood methylome analysis. European Journal of Endocrinology, 2022, 186, 297-308.	3.7	7
179	Concomitant therapies (glucocorticoids and sex hormones) in adult patients with growth hormone deficiency. Journal of Endocrinological Investigation, 2008, 31, 61-5.	3.3	7
180	Microsatellite (GT)(n) repeats and SNPs in the von Willebrand factor gene promoter do not influence circulating von Willebrand factor levels under normal conditions. Thrombosis and Haemostasis, 2009, 101, 298-304.	3.4	7

#	Article	IF	Citations
181	Prenatal dexamethasone treatment for classic 21-hydroxylase deficiency in Europe. European Journal of Endocrinology, 2022, 186, K17-K24.	3.7	7
182	How to rule out non-neoplastic hypercortisolemia (previously known as pseudo-cushing). Pituitary, 2022, 25, 701-704.	2.9	7
183	Medical Treatment for Acromegaly does not Increase the Risk of Central Adrenal Insufficiency: A Long-Term Follow-Up Study. Hormone and Metabolic Research, 2016, 48, 514-519.	1.5	6
184	Body Composition is Different After Surgical or Pharmacological Remission of Cushingâ€™s Syndrome: A Prospective DXA Study. Hormone and Metabolic Research, 2017, 49, 660-666.	1.5	6
185	Subpopulations of T lymphocytes in primary biliary cirrhosis. Clinical Immunology and Immunopathology, 1981, 20, 255-260.	2.0	5
186	A 10-year history of secondary hypertension. Journal of Hypertension, 2018, 36, 1772-1774.	0.5	5
187	PTH: Redefining Reference Ranges in a Healthy Populationâ€”The Role of Interfering Factors and the Type of Laboratory Assay. International Journal of Endocrinology, 2020, 2020, 1-7.	1.5	5
188	Cardiovascular autonomic dysfunction in patients with idiopathic diabetes insipidus. Pituitary, 2018, 21, 50-55.	2.9	4
189	Low-dose short synacthen test with salivary cortisol in patients with suspected central adrenal insufficiency. Endocrine Connections, 2021, 10, 1189-1199.	1.9	4
190	Different therapeutic options in patients with Cushing's syndrome due to bilateral macronodular adrenal hyperplasia. Minerva Endocrinologica, 2019, 44, 205-220.	1.8	4
191	Effect of a Synthetic Substituted Î±1-18 ACTH on Mineralocorticoid Secretion. Hormone and Metabolic Research, 1980, 12, 464-470.	1.5	3
192	HLA and hormonal studies in 5 patients with late-onset 21-hydroxylase deficiency syndrome (21 OHDS). Journal of Endocrinological Investigation, 1986, 9, 65-70.	3.3	3
193	Characteristics and outcomes of Italian patients from the observational, multicentre, hypopituitary control and complications study (Hypo<scp>CCS</scp>) according to tertiles of growth hormone peak concentration following stimulation testing at study entry. Clinical Endocrinology, 2015, 83, 527-535.	2.4	3
194	Pitfalls in urinary sodium excretion. Journal of Clinical Hypertension, 2019, 21, 1635-1636.	2.0	3
195	Prognostic significance of the sum of the diameters of single foci in multifocal papillary thyroid cancer: the concept of new-old tumor burden. Therapeutic Advances in Endocrinology and Metabolism, 2020, 11, 204201882096432.	3.2	3
196	The prevalence of secondary neoplasms in acromegalic patients: possible preventive and/or protective role of metformin. International Journal of Clinical Oncology, 2021, 26, 1015-1021.	2.2	3
197	Cost-effective therapy in patients with idiopathic hirsutism. Expert Review of Pharmacoeconomics and Outcomes Research, 2004, 4, 297-306.	1.4	2
198	Diagnostic and therapeutic challenge in the management of a patient with ectopic adrenocorticotropin secretion. Journal of Endocrinological Investigation, 2010, 33, 507-508.	3.3	2

#	Article	IF	Citations
199	The haemostatic system in acromegaly: a single-centre caseâ€“control study. Journal of Endocrinological Investigation, 2020, 43, 1009-1018.	3.3	2
200	Long-Lasting Effects of Spironolactone after its Withdrawal in Patients with Hyperandrogenic Skin Disorders. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2023, 23, 188-195.	1.2	2
201	The Role of Glucocorticoid Receptor in the Pathophysiology of Pituitary Corticotroph Adenomas. International Journal of Molecular Sciences, 2022, 23, 6469.	4.1	2
202	HLA AND HORMONAL DATA FOR IDENTIFICATION OF HETEROZYGOTES IN 11?- AND 17?-HYDROXYLASE DEFICIENCY SYNDROMES. Clinical and Experimental Pharmacology and Physiology, 1982, 9, 265-269.	1.9	1
203	Retinal abnormalities associated with a mutation of the nucleotide 683 in von Hippel-Lindau disease. Graefe's Archive for Clinical and Experimental Ophthalmology, 2000, 238, 615-620.	1.9	1
204	Hypercortisolism and pregnancy upregulate von Willebrand factor through different mechanisms: report on a pregnant patient with Cushing's syndrome. Blood Coagulation and Fibrinolysis, 2010, 21, 476-479.	1.0	1
205	The Adrenal Glands. Endocrinology, 2016, , 1-35.	0.1	1
206	Hypertension in Cushingâ€™s Syndrome. Updates in Hypertension and Cardiovascular Protection, 2020, , 127-139.	0.1	1
207	Incretin Response to Mixed Meal Challenge in Active Cushingâ€™s Disease and after Pasireotide Therapy. International Journal of Molecular Sciences, 2022, 23, 5217.	4.1	1
208	HLA and Hormonal Studies in 5 Patients with Late-Onset 21-Hydroxylase Deficiency Syndrome (210HDS). Obstetrical and Gynecological Survey, 1987, 42, 249-251.	0.4	0
209	Pathogenesis and clinical impact of relative adrenal insufficiency in hospitalized patients with acute decompensation of cirrhosis. Digestive and Liver Disease, 2015, 47, e7.	0.9	0
210	The Adrenal Glands. Endocrinology, 2018, , 387-421.	0.1	0